Immunovant, Inc. · NASDAQ:IMVT
Immunovant — Corporate Update (September 2022)
21 slides from Immunovant's corporate update, Sep 28, 2022
Slide 1: Building a Leading Franchise: Next Generation FcRn: IMVT-1402
CONFIDENTIAL Building a Leading Franchise Next Generation FcRn: IMVT-1402 September 2022 For Investor Audiences Only Exhibit 99.2
Slide 2: Forward-looking statements
CONFIDENTIAL Forward-looking statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,
Slide 3: Our vision: Normal lives for people with autoimmune disease
CONFIDENTIAL Our vision: Normal lives for people with autoimmune disease Driven by our core values 3 Love Trailblazing All Voices Bolder, Faster For Investor Audiences Only
Slide 4: Building a leading anti-FcRn franchise: Introducing IMVT-1402
CONFIDENTIAL Building a leading anti-FcRn franchise: Introducing IMVT-1402 4For Investor Audiences Only Novel, fully human, monoclonal antibody inhibiting FcRn- mediated recycling of IgG IMVT-1402 + + + + + + IMVT-1402 is the successful culmination of in-house development Animal studies1 have demons
Slide 5: FcRn inhibition has broad potential in autoimmune diseases
CONFIDENTIAL FcRn inhibition has broad potential in autoimmune diseases: 19 announced indications1 across multiple therapeutic areas create clinical and commercial2 opportunity for a franchise approach 5 ENDOCRINOLOGY Thyroid eye disease (TED) Graves’ disease RHEUMATOLOGY Primary Sjogrens syndrome S
Slide 6: Anti-FcRn market is unique in breadth of indications and strong biomarker
CONFIDENTIAL Anti-FcRn market is unique in terms of breadth of potential indications and in terms of having a strong biomarker 6For Investor Audiences Only IgG reduction is a well-established biomarker for degree of clinical response1 Some patient populations and indications likely need maximal IgG
Slide 7: Next generation anti-FcRn: IMVT-1402
Next generation anti-FcRn: IMVT-1402
Slide 8: IMVT-1402 has potentially best-in-class attributes to address large unmet need
IMVT-1402 has potentially best-in-class attributes to address large unmet need in autoimmune disease 8 01 02 03 8For Investor Audiences Only DEEP IgG LOWERING Animal studies suggest deep dose-dependent IgG lowering similar to batoclimab1 FAVORABLE ANALYTE PROFILE Animal studies support the potential
Slide 9: IMVT-1402 and batoclimab demonstrated similar, maximum IgG reduction
CONFIDENTIAL -100 -50 0 50 100 0 7 14 21 28 35 42 56 • 20 monkeys, dosed IV in head-to-head study across four groups • At comparable doses, IgG lowering is similar for both batoclimab and IMVT-1402 • Cynomolgus monkeys observed to be reliable pharmacodynamic proxy for anti-FcRn mediated impacts on I
Slide 10: IMVT-1402 and placebo demonstrated similar albumin and LDL
CONFIDENTIAL 10 IMVT-1402 and placebo demonstrated similar albumin and LDL For Investor Audiences Only Day SD, standard deviation; ULN, upper limit of normal; LLN, lower limit of normal; Arrows indicate time of dosing. Data on file at Immunovant Day Batoclimab 50 mg/kg (n=3) IMVT-1402 50 mg/kg (n=7)
Slide 11: IMVT-1402 designed to maximize IgG reduction while minimizing albumin interference
CONFIDENTIAL IMVT-1402 is designed to deliver maximum IgG reduction while minimizing interference with the albumin binding site Albumin FcRn Batoclimab Albumin IMVT-1402 FcRn Batoclimab IMVT-1402 11For Investor Audiences OnlyNote: Ribbon representations generated from X-Ray crystal structure. Batocl
Slide 12: IMVT-1402 development is well underway, with initial Phase 1 data expected mid-2023
IMVT-1402 development is well underway, with initial Phase 1 data expected in mid-2023 12 Ongoing in-house development GMP drug product manufacture completed 6-week nonclinical studies completing shortly with IND filing planned in early 2023 Initial Phase 1 data expected in mid-2023 IMVT-1402 develo
Slide 13: Anti-FcRn Franchise Strategy
CONFIDENTIAL Anti-FcRn Franchise Strategy 13
Slide 14: Building an anti-FcRn franchise with differentiated assets
Building an anti-FcRn franchise with differentiated assets to address a range of patient needs 14 Tailored dosing to address varying symptom severity across indications and stage of disease • Short term maximal IgG suppression • Lower chronic doses where less IgG suppression needed • Fixed duration
Slide 15: Differentiated assets and a rational development strategy
Building an anti-FcRn franchise with differentiated assets and a rational development strategy to optimize ability to address unmet need 15 Induction and Maintenance in MG, CIDP Fixed Duration in TED ++ + + Batoclimab IMVT-1402 Sustained, maximal IgG suppression in additional therapeutic areas such
Slide 16: Leveraging batoclimab learnings to accelerate IMVT-1402 development
CONFIDENTIAL 16For Investor Audiences Only Planning to leverage data and learnings from batoclimab to accelerate development of IMVT-1402 Potential case study in Graves’ Disease Batoclimab Phase 2 trial in Graves’ Disease to define effect size and trial design IMVT-1402 dosing to be informed by para
Slide 17: Batoclimab and IMVT-1402 potential differentiated product features
CONFIDENTIAL Batoclimab and IMVT-1402 have the potential to offer multiple differentiated product features, if approved 17 Product and program attributes efgartigimod1 batoclimab IMVT-14022 IgG reduction ~65% X X X IgG reduction ~80% X X Albumin/LDL changes: none or minimal X X Subcutaneous (SC) for
Slide 18: Franchise value is maximized by developing both batoclimab and IMVT-1402
CONFIDENTIAL We believe franchise value is maximized by developing both batoclimab and IMVT-1402 18For Investor Audiences Only Lead asset batoclimab full speed ahead in pivotal programs for MG, TED and CIDP Earlier batoclimab launches may provide faster path to positive cash flow and enable commerci
Slide 19: Immunovant
YY IMMUNOVANT + ++ + + prs + + + ++ +
Slide 20: Multiple paths to enhanced value creation when developed together
CONFIDENTIAL Multiple paths to enhanced value creation when batoclimab and IMVT-1402 are developed together 20For Investor Audiences Only GD: Phase 2 Trial Initiation GD: Initial Results at 12 and 24 weeks MG: Topline Results 2023 2024 2025 MG: Phase 3 Trial Initiation TED: Initiation of Phase 3 tri
Slide 21: A leader in FcRn inhibitor technology
CONFIDENTIAL A leader in FcRn inhibitor technology dedicated to enabling normal lives for people with autoimmune diseases 21 Batoclimab full speed ahead in MG, TED and CIDP IMVT-1402 designed for differentiation across the key product features for anti-FcRns Multiple paths to enhanced value creation